Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell PLC fund raise well-backed as trial pace quickens

A hot area of cancer research at present, immunotherapy uses the body's own internal biological defences to ward off the disease,
Scancell PLC fund raise well-backed as trial pace quickens
The proceeds of the placing, at 17p, will support both product lines.

-- adds firm placing details --

Immunotherapy group Scancell PLC (LON:SCLP)  has seen strong support from institutions for a fund raise to develop its two lead platform technologies.

A hot area of cancer research at present, immunotherapy uses the body's own internal biological defences to ward off the disease with the ultimate hope to build up long-term resistance.

This tumour-specific T-cell technique in particular has been given a major boost by results from recent studies, but Scancell, is targeting the disease long before it reaches the stage of patients in these recent trials.

Its vaccine platform, Immunobody, can be designed to target a particular cancer. Moditope, meanwhile, is a peptide-based vaccine platform that stimulates the production of killer CD4+ T cells that induce anti-tumour activity without toxicity. 

The proceeds of the placing, at 17p, will support both product lines. The firm placing raised £400,000 more than expected at £3.4mln, while an open offer aims to raise a further £3.8mln.

John Chiplin, Scancell’s chairman, said: "We are also excited to be progressing the first pipeline product from our Moditope platform, Modi-1, into the clinic.

“Part of the funds raised are earmarked for finishing the necessary work to allow Scancell to file a Clinical Trial Application in the UK for the planned Phase 1/2 clinical trial in triple negative breast cancer/ovarian cancer that we expect to begin next year."

PhilW.jpg
Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile

Scancell Holdings Plc Timeline

Article
August 22 2016

Related Articles

Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin
Diagnostic test
July 26 2016
The timetable for the HCV test trials is relatively short
Pollen2.jpg
July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.